BPC-157 in New Zealand: Status, Research and Availability

At a glance

BPC-157 is a synthetic peptide studied in preclinical and animal literature. In New Zealand it is a scheduled substance: as of the Poisons Standard amendment that took effect on 1 June 2024, BPC-157 is listed in Schedule 4 (Prescription Only Medicine) and in Appendix D. It is not approved by the Therapeutic Goods Administration (TGA) and it does not appear on the New Zealand Register of Therapeutic Goods (ARTG).

Where BPC-157 is offered by research-supply vendors in New Zealand, it is sold strictly for laboratory and research purposes and not for human or veterinary use. This page explains that status, outlines the published research context in neutral terms, and covers how buyers assess quality and documentation. It does not provide dosing, protocols or any health guidance.

Current regulatory status in New Zealand

BPC-157 was added to the New Zealand Poisons Standard (the SUSMP) through an amendment that commenced on 1 June 2024. The substance was entered in Schedule 4, which covers Prescription Only Medicines, and also in Appendix D, which lists substances subject to additional controls on possession and supply.

Separately from scheduling, BPC-157 has not been evaluated and registered by the TGA for therapeutic use. It is not listed on the ARTG, which is the register of therapeutic goods that may lawfully be supplied in New Zealand for human use. Sport Integrity New Zealand describes BPC-157 as an experimental substance that is not approved by the TGA or by any comparable overseas regulator for human use.

What the status means in practice

• BPC-157 is treated as a prescription-only medicine under the Poisons Standard.
• It is not a TGA-approved therapeutic good and is not on the ARTG.
• Appendix D adds further controls, which is why research-supply vendors frame the product as laboratory material only.
• Classifications are set at the Commonwealth level and then adopted by state and territory law, so local obligations can differ.

What research-use-only actually means

Research-use-only (RUO) is a supply and labelling category, not a loophole and not an endorsement of any use in people. When a peptide is sold as RUO, the vendor is stating that the material is intended for laboratory research, such as in vitro work or analytical method development, and is not supplied as a medicine, supplement, food or cosmetic.

RUO material is generally not manufactured, tested or released to the standards required for therapeutic goods. It carries no approved indication, no patient information and no claim of safety or efficacy in humans. Treating RUO material as if it were an approved medicine would ignore the reason the category exists.

Typical features of research-use-only supply

• Labelled for laboratory research, not for human or veterinary use.
• No therapeutic claims, dosing instructions or administration guidance.
• Sold to researchers and institutions who hold their own responsibilities for lawful handling.
• Accompanied by analytical documentation such as a certificate of analysis rather than patient-facing information.

Research background, stated neutrally

BPC-157 is often described in the literature as a synthetic pentadecapeptide, meaning a chain of fifteen amino acids. Its sequence corresponds to a fragment identified in a protein present in human gastric juice. In published work it is sometimes referred to by other names, including pentadecapeptide BPC 157, PL 14736 and Bepecin.

The published research on BPC-157 is overwhelmingly preclinical. It consists of laboratory studies and animal models exploring tissue and cellular responses. This body of work is the reason BPC-157 is of interest as a research reagent. It does not establish safety or effectiveness in humans, and no such conclusions should be drawn from it.

Where BPC-157 sits in the New Zealand research-supply landscape

Because BPC-157 is scheduled and not an approved medicine, it does not appear through ordinary consumer or retail channels in New Zealand. Within the research-supply landscape it sits alongside other peptides that are studied in the laboratory but have no approved human indication, such as TB-500. These are handled as reagents, described by their chemical identity and documented with analytical paperwork rather than marketed with health claims.

The practical picture for a researcher is that BPC-157 is a controlled, specialist item. Supply is narrower than for unscheduled laboratory chemicals, documentation expectations are higher, and responsible vendors keep their framing firmly on research use. The absence of an approved product means there is no reference medicine to compare against, which places more weight on the quality of the supplier and their testing.

Assessing quality and CoA when sourcing for research

When BPC-157 is sourced as a research reagent, the most useful signal of quality is independent analytical documentation. A certificate of analysis (CoA) reports what testing found for a specific batch and lets a researcher judge identity and purity rather than relying on a label alone.

What to look for in documentation

• A batch or lot number on the CoA that matches the vial you receive.
• Purity measured by a method such as high performance liquid chromatography (HPLC).
• Identity or mass confirmation, for example by mass spectrometry.
• A recent test date, and ideally testing performed or verified by an independent laboratory.
• Clear research-use-only labelling with no therapeutic or dosing claims.

Treat a missing, generic or unverifiable CoA as a red flag. A certificate that does not tie to a batch, or that cannot be traced to a testing laboratory, offers little assurance. Consistent documentation across orders, transparent storage and handling notes, and a vendor who stays within research-use framing are all reasonable things to weigh.

Availability realities

Scheduling shapes availability. Because BPC-157 is a Schedule 4 and Appendix D substance that is not on the ARTG, it is not stocked as a general consumer product, and availability through research-supply channels can be inconsistent. Stock, batch availability and documentation can vary between suppliers and over time.

Buyers should also expect the regulatory picture itself to move. The Poisons Standard is revised on a regular cycle, enforcement focus can shift, and platform and payment rules around peptides change frequently. What is accurate on any given date should be reconfirmed against primary sources rather than assumed to be permanent.

Availability is a function of scheduling and supplier diligence, not of demand. High search interest does not change the regulatory status.

Sport and anti-doping status

BPC-157 is relevant to anyone bound by anti-doping rules. It has been on the World Anti-Doping Agency (WADA) Prohibited List since 1 January 2022, in category S0 (Non-Approved Substances), which is prohibited at all times, both in and out of competition. Sport Integrity New Zealand lists BPC-157 on this basis and advises athletes to check substances through official channels such as Global DRO.

For researchers this is context rather than a dosing matter, but it reinforces the point that BPC-157 is a non-approved substance in regulated settings and should not be treated as a consumer wellness product.

Frequently asked questions